Oral renal anemia drug meets reimb listing terms
By Nho, Byung Chul | translator Kang, Shin-Kook
24.05.22 05:35:15
가나다라
0
EPO injectables have dominated a KRW 100 billion market for the past 30 years…prescriptions on the rise
Licensed oral renal anemia drugs 'Vadanem·Enaroy' cost 30% less than conventional drugs
FDA granted approval of Vadanem, with proven safety…oral formulation has the benefit of reducing costs·convenience for administration
▲Mitsubishi Tanabe Pharma and JW Pharmaceutical have filed an application to the Health Insurance Review and Assessment Service (HIRA) for drug pricing of licensed renal anemia drugs, Vadanem and Enaroy.
An application for drug pricing has been filed for two items of renal anemia drugs that are equivalent in efficacy to conventional EPO injections but cost much less. New treatment options are expected to become available.
According to industry sources, Mitsubishi Tanabe Pharma and JW Pharmaceutical have filed an application to the Health Insurance Review and Assessment Service (HIRA) for drug pricing of licensed renal anemia drugs, Vadanem and Enaroy.
The insurance pricing of these drugs is about KRW 1.2 million, which is about KRW 300,000-500,000 lower annually than EPO injections. It is expected to significantly save the finances of the National Health Insurance.
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)